SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ImmunityBio converts from Immunomedics
IBRX 2.139+0.9%Nov 7 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: zagnut12/19/2025 10:07:30 AM
3 Recommendations

Recommended By
Davidoff
erippetoe
rodneyh07

   of 1229
 
Next-generation recombinant Bacillus Calmette-Gurin has undergone Phase 2 clinical trials in Europe in non-muscle invasive bladder cancer.Supplies of rBCG are now available, with shipments set to begin immediately via an FDA Expanded Access Program.Multiple U.S. patents issued and allowed on combination of BCG plus ANKTIVA.Thousands of vials of rBCG available to end shortage of TICE BCG.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News